These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
6. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Shepherd J; Betteridge J; Van Gaal L; Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866 [TBL] [Abstract][Full Text] [Related]
9. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Florkowski CM Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995 [TBL] [Abstract][Full Text] [Related]
10. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia. Bell DS Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642 [TBL] [Abstract][Full Text] [Related]
11. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus. Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747 [TBL] [Abstract][Full Text] [Related]
12. Management of dyslipidemia in adults with diabetes. Haffner SM Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988 [TBL] [Abstract][Full Text] [Related]
13. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]
15. Treatment of diabetic dyslipidemia. Garg A Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814 [TBL] [Abstract][Full Text] [Related]
16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
17. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Krentz AJ Diabetes Obes Metab; 2003 Nov; 5 Suppl 1():S19-27. PubMed ID: 14984018 [TBL] [Abstract][Full Text] [Related]
18. Triglyceride as a risk factor for coronary artery disease. Gotto AM Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100 [TBL] [Abstract][Full Text] [Related]
19. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes. Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764 [TBL] [Abstract][Full Text] [Related]
20. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Niemeijer-Kanters SD; Dallinga-Thie GM; de Ruijter-Heijstek FC; Algra A; Erkelens DW; Banga JD; Jansen H Atherosclerosis; 2001 May; 156(1):209-16. PubMed ID: 11369016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]